Skip to content
Menu

Wedbush Maintains Neutral on Compass Therapeutics, Lowers Price Target to $0.9

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Robert Driscoll maintains Compass Therapeutics (NASDAQ:CMPX) with a Neutral and lowers the price target from $1 to $0.9.

Wedbush analyst Robert Driscoll maintains Compass Therapeutics (NASDAQ:CMPX) with a Neutral and lowers the price target from $1 to $0.9.

Read at benzinga.com